BioSpace News Archive

Proteros biostructures GmbH, an expert in integrated structure-based drug discovery, announces an expansion of its collaboration with AstraZeneca focused on the discovery and development of novel epigenetic drugs.

Eliem Therapeutics, Inc. provided a business update and reported financial results for the quarter ended March 31, 2022.

NanoViricides, Inc. a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform reports that it has begun drug development to combat recent cases of severe pediatric hepatitis.

atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today reported financial results for the quarter ended March 31, 2022 and provided a business update.

Protalix BioTherapeutics, Inc. today reported financial results for the first quarter ended March 31, 2022 and provided a business update on recent corporate and clinical developments.

ObsEva SA announced that Company Management will provide a corporate update at the upcoming H.C. Wainwright Global Investment Conference, taking place virtually and in Miami, Florida from May 23 – 26, 2022.

Galera Therapeutics, Inc. announced its intent to file a New Drug Application for avasopasem manganese for the treatment of radiotherapy-induced severe oral mucositis in patients with locally advanced head and neck cancer with the U.S. Food and Drug Administration by the end of 2022.

Windtree Therapeutics, Inc. announced management will host a conference call and webcast to discuss its istaroxime Phase 2 study in early cardiogenic shock patients following the late-breaker presentation of the data at the European Society of Cardiology Heart Failure Meeting in Madrid, Spain on May 23, 2022.

Taysha Gene Therapies, Inc. reported financial results for the first quarter ended March 31, 2022 and provided a corporate update.

Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today reported financial results for the first quarter ended March 31, 2022, and provided an overview of recent operational highlights and a pipeline update.